Vitamin B Supplementation as Treatment for Episodic Migraine in Women
Presenting at AHS 2022, researchers examined the effects of supplementation of B vitamins and a combination of these vitamins on women with episodic migraine.
Migraine
Clinical Challenge: Bilateral Blurry Vision
A man in his late 40s comes to the emergency department with a complaint of blurry vision that lasted for approximately 20 minutes before returning to normal. The loss of focused vision affected both eyes. Can you make the diagnosis?
Yoga Therapy for Migraine: Can It Help Reduce Headache Frequency?
In a meta-analysis, researchers examined the efficacy of yoga therapy as a treatment for patients with migraine.
FDA to Review Intranasal Zavegepant for Migraine Treatment
The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.
Atogepant Reduces Monthly Migraine Days in Chronic Migraine Trial
The PROGRESS study compared the efficacy and safety of atogepant to placebo in 778 adults with at least a 1-year history of chronic migraine.
Migraine-Diet Connection: Dietary Triggers and Interventions for Migraine Management
Lauren R. Natbony, MD, takes us on a deep dive into the association between nutrition and dietary patterns in migraine, including proposed mechanisms, and the remaining needs in patient education and research.
Erenumab vs Topiramate in Patients With Migraine: Head-to-Head Study Results
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Understanding Chronic Migraine: From Pathophysiology to Treatment Disparities
An expert roundtable of headache specialists helps outline chronic migraine as its own entity, disparities and barriers to treatment, and a need for better research and education.
Newer Pharmacotherapies Compared With Triptans for Migraine Treatment
The analysis included 64 randomized clinical trials with a total of 46,442 patients.
Trudhesa Nasal Spray Now Available for Acute Treatment of Migraine
Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space.
- Loading...
Loading...
Next post in News
Loading... 
Loading...